Glenmark
Glenmark Announces Results of Phase 3 Clinical Trial of Favipiravir on COVID Patients
Glenmark’s Favipiravir is Different from Livealth Bio Pharma’s Livfavir
Glenmark: Antiviral Favipiravir To Enter into Phase 3 of Clinical Trials
/smstreet/media/agency_attachments/3LWGA69AjH55EG7xRGSA.png)
/smstreet/media/post_banners/K8ZMXAhGC6Kc5X2ZUwJW.jpg)
/smstreet/media/post_banners/BtMqFPKcDwTyO19RusaX.jpg)
/smstreet/media/post_banners/HIrTI7VHY7cpyDkakHG3.jpg)
/smstreet/media/post_banners/9zf8tBMgsOhX2Ok2nXi4.jpg)
/smstreet/media/post_banners/RJvRfzXUymLRquYdA2EI.jpg)
/smstreet/media/post_banners/jv0PCxH4pJdcWVeW1eh4.jpg)
